



**FOR IMMEDIATE RELEASE**

**Media Contact:**

Patrick MacCarthy, NinePoint Medical, Inc.

(617) 475-2361 / [pmacCarthy@ninepointmedical.com](mailto:pmacCarthy@ninepointmedical.com)

**NinePoint Medical to Feature the NvisionVLE® Imaging System with Real-time Targeting™ at DDW 2017; Twenty-four Scientific Abstracts to be Presented**

**Bedford, Mass. – May 5, 2017 – [NinePoint Medical, Inc.](#)**, a transformative medical device company pioneering the use of advanced Optical Coherence Tomography (OCT) for gastrointestinal applications, will be featuring the NvisionVLE® Imaging System with Real-time Targeting™ at [Digestive Disease Week®](#) (DDW) 2017, which will be held May 6-9 in Chicago. In addition, results from various studies utilizing this technology in gastroenterology will be presented in 24 scientific abstracts throughout the conference.

Random biopsy is the current standard of care for diagnosing esophageal diseases such as Barrett’s esophagus, squamous cell carcinoma, and adenocarcinoma. However, random biopsies assess less than 3% of the esophageal surface<sup>1</sup>, leaving more than 97% of the tissue un-sampled. The [NvisionVLE Imaging System](#) rapidly evaluates 100% of the esophageal tissue at a depth of 3mm and may identify disease that is not visible with conventional medical imaging technologies such as endoscopy or ultrasound. Now, with the addition of the Real-time Targeting feature, physicians can not only locate, but also mark areas of interest for targeted biopsy or treatment.

“Real-time Targeting has increased my confidence in detecting and targeting potential disease that may exist below the surface of the esophagus,” stated Dr. Kenneth Chang, MD, University of California Irvine Medical Center, Professor and Chief, Division of Gastroenterology. “Finding dysplastic or cancerous cells in patients with Barrett’s Esophagus can be like looking for a needle in a haystack. This technology may help us not only

in finding the needle, but also in determining the most effective therapy. It has become an integral part of my practice.”

“We are very appreciative of the many clinicians who have contributed to the rapidly growing body of scientific evidence supporting the use of Optical Coherence Tomography (OCT) in gastroenterology, through their many abstract submissions for DDW 2017”, stated Christopher von Jako, PhD., President and CEO of NinePoint Medical. “We are excited to showcase our new Real-time Targeting feature, which has transformed the clinical use of OCT and is helping physicians find disease earlier, so it can be treated effectively.”

NinePoint Medical will be exhibiting at booth # 4028 during DDW 2017.

### **About Esophageal Disease**

Esophageal adenocarcinoma (EAC) is the fastest growing cancer in the western world, increasing in incidence more than 7-fold over the past several decades.<sup>2</sup> Barrett’s esophagus, a complication of gastroesophageal reflux disease (GERD), affects more than 12 million American adults,<sup>3</sup> and is associated with a 30-fold increased risk of developing EAC.<sup>4</sup>

### **About the NvisionVLE® Imaging System**

The [NvisionVLE Imaging System](#) provides a unique and clinically valuable new perspective of esophageal disease: The ability to image within the wall of the esophagus. By providing a high-resolution, real-time scan of the esophagus using Optical Coherence Tomography (OCT) – a technology similar to ultrasound but using infrared light rather than sound waves - the system enables physicians to perform a Volumetric Laser Endomicroscopy (VLE) procedure and view structures not evident with conventional imaging, and potentially identify disease that would have otherwise been missed. With the recent addition of a Real-time Targeting feature, physicians can not only locate, but now mark areas of interest. This marking feature, in combination with an improved workflow, enables more accurate targeting, potentially leading to improved diagnosis and more effective therapeutic decisions for patients. Since the NvisionVLE® Imaging System has been cleared by the FDA, approximately 10,000 VLE procedures have been performed in the U.S.

### **About NinePoint Medical, Inc.**

[NinePoint Medical](#) is a privately-held medical device company that designs, manufactures, and sells an Optical Coherence Tomography (OCT) imaging platform for clinical use in gastroenterology, pulmonology, urology, gynecology, and ENT, for the evaluation of human tissue microstructure. Using proprietary imaging and software technology, the Company is committed to enabling quicker diagnosis of disease and more effective

treatments, while reducing the overall cost of healthcare. NinePoint Medical is located in suburban Boston, Massachusetts. For more information, please visit [www.ninepointmedical.com](http://www.ninepointmedical.com).

**References:**

1. Chandrasoma PT, DeMeester TR. GERD: Reflux to Esophageal Adenocarcinoma. Academic Press. 2010
2. Pohl H, Sirovich B, Welch HG. Esophageal adenocarcinoma incidence: are we reaching the peak? *Cancer Epidemiol Biomarkers Prev* 2010;19:1468-70
3. Hayeck TJ, Kong CY, Spechler SJ, Gazelle GS, Hur C. The prevalence of Barrett's esophagus in the U.S.: estimates from a simulation model confirmed by SEER data. *Dis Esophagus* 2010;23:451-7
4. Solaymani-Dodaran, M., Logan, R. F. A., West, J., Card, T., Coupland, C. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. *Gut*, 2004; 53(8), 1070-1074